Oncology Impact Fund (Cayman) Management L.P., 10% Owner at iTeos Therapeutics, Inc. (ITOS), sold 305,422 shares at $28.82 ($8.7M) on 2021-09-17, disclosed to the SEC on 2021-09-20.
Open-market sale of $8.7M ITOS by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $28.47 | 35,565 | $1.0M | 11.7% |
| 2 | $28.47 | 35,565 | $1.0M | 11.7% |
| 3 | $28.82 | 76,473 | $2.2M | 25.4% |
| 4 | $28.82 | 76,473 | $2.2M | 25.4% |
| 5 | $27.03 | 17,743 | $480K | 5.5% |
| 6 | $27.03 | 17,743 |
| $480K |
| 5.5% |
| 7 | $27.84 | 22,930 | $638K | 7.4% |
| 8 | $27.84 | 22,930 | $638K | 7.4% |
| Total | $28.38 avg | 305,422 | $8.7M | 100% |
| Filing → |
| ITOS | SELL | 2021-11-24 | $8.9M | — | Filing → |
| ITOS | SELL | 2021-10-18 | $1.6M | — | Filing → |
| ITOS | SELL | 2021-10-12 | $4.6M | — | Filing → |